Creative Touch Permanent Makeup and Aesthetics

The senescence-associated secretory phenotype (SASP) is the collection of proteins, proteases, and signalling molecules that a senescent cell secretes into its surrounding tissue environment. Rather than simply arresting and going quiet, a senescent cell remains metabolically active and continuously releases this secretory output – making the SASP the primary mechanism through which accumulated senescent cells influence tissue function far beyond their own individual arrest. In skin, SASP-driven inflammation and matrix degradation are central contributors to the structural and functional changes that characterise both chronological and UV-accelerated ageing.

What the SASP Contains

Research using primary human dermal fibroblasts has characterised the core SASP components as falling into three functional groups. ^[3]

Pro-inflammatory cytokines – IL-6, IL-8, IL-1β, and TNF-α are consistently expressed across senescent cell types and tissue contexts. IL-6 is particularly significant in skin: it is highly upregulated in senescent dermal fibroblasts, reinforces the senescent state through JAK/STAT3 signalling, and induces paracrine senescence in surrounding cells. ^[4] IL-6 and IL-8 are considered the canonical SASP markers – consistently present across senescence triggers and cell types even when other components vary. ^[5]

Matrix metalloproteinases (MMPs) – MMP-1, MMP-3, MMP-10, and MMP-14 have all been identified in the SASP of senescent dermal fibroblasts. ^[4] MMP-1 is the primary collagenase responsible for cleaving fibrillar Type I and Type III collagen; its sustained elevation in SASP-secreting tissue explains why photoaged skin – carrying a higher senescent fibroblast burden from SIPS – shows accelerated collagen fragmentation and disorganisation relative to chronologically matched sun-protected skin. ^[2]

Growth factors and other mediators – VEGF, IGFBP family members, and plasminogen activator inhibitor-1 (PAI-1) are also consistently present, reflecting the SASP’s origin as a wound-signalling mechanism as much as a pro-inflammatory one.

How SASP Is Regulated: Two Transcriptional Drivers

SASP expression is not controlled by a single pathway. Two transcription factors drive SASP output through related but distinct routes, a distinction with direct relevance to therapeutic targeting.

NF-κB is the primary transcriptional driver of SASP cytokine expression. Once activated during senescence establishment, NF-κB translocates to the nucleus and drives IL-6, IL-8, IL-1β, TNF-α, and MMP gene expression – the core pro-inflammatory and matrix-degrading SASP components. NF-κB activation is self-reinforcing: SASP cytokines feed back to maintain NF-κB activity, creating a self-amplifying inflammatory loop in chronically senescent tissue. ^[4]

p38-MAPK functions as a DNA damage response-independent regulator of the SASP – operating on a delayed timescale that parallels SASP development rather than the immediate DNA damage response. Critically, p38-MAPK regulates the SASP primarily through NF-κB: it increases NF-κB transcriptional activity, making it an upstream driver rather than a parallel pathway. Constitutive p38-MAPK activation is sufficient to induce SASP expression independently of the DDR, and p38-MAPK inhibition suppresses SASP output through consequent NF-κB reduction. ^[1] This is the mechanistic basis for p38-MAPK inhibitors as a senomorphic therapeutic target – their SASP-suppressive effect operates upstream of and independently from the DNA damage response itself.

SASP Is Not Uniform

One of the most clinically relevant aspects of SASP biology – and the aspect most frequently absent from lay content – is that its composition is not fixed. Research has confirmed that SASP profiles vary across both stimulus type and tissue context, with both core components (IL-6, IL-8, MMP-1) and stimulus-specific components present in profiles from different senescence triggers. ^[3] UV-induced SASP in dermal fibroblasts differs from replicative SASP in the same cell type – meaning the inflammatory and matrix-degrading consequences of photoaged skin are not simply a faster version of chronological ageing but a qualitatively different secretory environment. Duration also matters: early senescent cells produce a moderate SASP that is relatively growth-factor-rich, whilst chronically senescent cells develop an amplified, more pro-inflammatory output through progressive NF-κB self-amplification over time.

Paracrine Senescence: SASP as a Propagation Signal

Beyond its direct inflammatory and matrix-degrading effects, SASP can induce senescence in neighbouring non-senescent cells through paracrine signalling – a bystander effect that allows a localised senescent population to expand senescent burden laterally through tissue. In skin, senescent keratinocytes secrete IP-10 (CXCL10), which binds CXCR3 receptors on adjacent cells and transmits a senescence-inducing signal. ^[6] IL-6, through JAK/STAT3, reinforces this paracrine loop in dermal fibroblasts. This propagation mechanism is one of the reasons why a relatively small initial senescent burden can amplify into a widespread tissue-level problem over time – and why interventions that reduce SASP output (senomorphics, NF-κB suppression) have benefits beyond the senescent cells directly targeted.

The SASP in Context: Beneficial and Harmful

SASP is not inherently pathological. In wound healing, the acute SASP of transiently senescent wound-edge fibroblasts – rich in PDGF-AA – drives myofibroblast differentiation and tissue repair before those cells are cleared by NK cells and macrophages. In embryonic development, SASP signalling coordinates tissue patterning. The harm arises when senescent cells accumulate beyond the immune system’s clearance capacity and SASP transitions from an acute, contextually appropriate signal to a chronic, self-amplifying inflammatory environment. Understanding this distinction is essential to understanding both why the SASP evolved and what effective therapeutic approaches are actually targeting – they aim to reduce the accumulated chronic SASP burden, not eliminate the transient acute SASP that normal repair requires.